Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients;Schildwächterlymphknotenexzision (SLKE) und positronenemissionstomographie (PET). Staginguntersuchungen bei Melanompatienten in den klinischen Stadien I-II (nach DDG): Erfahrungen aus der Hautklinik Dortmund

Hautarzt

Volumn 54, Issue 5, 2003, Pages 440-447

  Schafer A ^a,d   Herbst, R A ^a   Beiteke, U ^a   Lange Ionescu, S ^a   Treckmann, H ^b   Lohlein D ^b   Thiemann, G ^c   Theophil, B ^c   Schwarze, E W ^d   Bartels, H J ^e   Frosch, P J ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Chirurgische Klinik   (Germany)

^c Strahlentherapie und Nuklearmedizin   (Germany)

^d KLINIKUM DORTMUND   (Germany)

^e Praxis für Radiologie   (Germany)

Author keywords

Melanoma; Positron emission tomography; Sentinel lymph node excision; Staging

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SENTINEL LYMPH NODE; TUMOR GROWTH; TUMOR VOLUME;

EID: 12444333162     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-002-0453-6     Document Type: Article

References (32)

1. Garbe C, McLeod GR, Buettner PG (2000) Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 89:1269-1278
2. Gershenwald JE, Thompson W, Mansfield PF et al. (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983
3. Morton DL, Thompson JF, Essner R et al. (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for earlystage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453-463
4. Cochran AJ, Balda BR, Starz H et al. (2000) The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 89:236-241
5. Habal N, Giuliano AE, Morton DL (2001) The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer. Semin Oncol 28:41-52
6. Koller J, Hantich B (1998) Sentinel lymph node detection. Ein neuer Ansatz in der Primärdiagnostik und Therapie des malignen Melanoms, In: Garbe C, Rassner G (Hrsg) Dermatologie: Leitlinien und Qualitätssicherung für Diagnostik und Therapie, Springer, Berlin Heidelberg New York Tokyo, S 271-273
7. Starz H, Balda B-R, Büchels H (1998) Sentinel-Lymphonodektomie bei malignen Melanomen. Eine vorläufige Bilanz aus histomorphologischer Sicht. In: Garbe C, Rassner G (Hrsg) Dermatologie: Leitlinien und Qualitätssicherung für Diagnostik und Therapie. Springer, Berlin Heidelberg New York Tokyo, S 274-277
8. Balch CM, Buzaid AC, Atkins MB et al. (2000) A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88:1484-1491
9. Holder WD Jr, White RL Jr, Zuger JH et al. (1998) Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227:764-769; discussion 769-771
10. Acland KM, Healy C, Calonje E et al. (2001) Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 19:2674-2678
11. Tyler DS, Onaitis M, Kherani A et al. (2000) Positron emission tomography scanning in malignant melanoma. Cancer 89:1019-1025
12. Wagner JD, Schauwecker D, Davidson D et al. (1999) Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in Melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508-1515
13. Kaufmann R, Tilgen W, Garbe C (1998) Malignes Melanom. Standards Dermatologische Onkologie. Hautarzt 48 [Suppl 1]:530-38
14. Wagner JD, Gordon MS, Chuang TY et al. (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462
15. Ulrich J, Otto HJ, Roessner A et al. (2000) Repräsentative Ergebnisse der Schildwächter-Lymphknoten-Exstirpation (SLKE) beim malignen Melanom. In: Plettenberg A, Meigel WN, Moll I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend, Springer, Berlin Heidelberg New York Tokyo, 533-537
16. Starz H, Balda BR, Kramer KU et al. (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110-2121
17. Gadd MA, Cosimi AB, Yu J et al. (1999) Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 134:381-387
18. Gershenwald JE, Colome MI, Lee JE et al. (1998) Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I of II melanoma. J Clin Oncol 16:2253-2260
19. Crippa F, Leutner M, Belli F et al. (2000) Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 41:1491-1494
20. Klein M, Freedman N, Lotem M et al. (2000) Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. Nuklearmedizin 39:56-61
21. Blessing C, Feine U, Geiger L et al. (1995) Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermato. 131:1394-1398
22. Baum RP, Rinne D, Kaufmann R (2000) Klinischer Stellenwert der Positronenemissionstomographie im Primärstaging und in der Nachsorge des malignen Melanoms. Nuklearmediziner 23:377-390
23. Fierlbeck G, Metzger S, Dohmen M et al. (2001) Prospective evaluation of FDG positron emissions tomography in staging of regional lymph nodes in patients with malignant melanoma. Melanoma Res 11 [Suppl 2001]
24. Reske SN, Bares R, Bull U et al. (1996) Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Nuklearmedizin 35:42-52
25. Reske SN (1998) Positronen-Emissions-Tomographie in der Onkologie. Dtsch Ärztebl 95:A-1847
26. Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82:1664-1671
27. von Schulthess GK, Steinert HC, Dummer R, Weder W (1998) Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad RadiolS [Suppl 2]:S300-302
28. Thomas JM, Patocskai EJ (2000) The argument against sentinel node biopsy for malignant melanoma. BMJ 321(7252):3-4
29. Bostick PJ, Morton DL, Turner RR et al. (1999) Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17:3238-3244
30. Lukowsky A, Bellmann B, Ringk A et al. (1999) Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol 113:554-559
31. Blaheta HJ, Ellwanger U, Schittek B et al. (2000) Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 114:637-642
32. Rayatt SS, Hettiaratchy SP, Key A, Powell BW (2000) Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits. BMJ 321:1285